Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

Original Article

A.M. Eggermont, C.U. Blank, M. Mandala, G.V. Long, V. Atkinson, S. Dalle, A. Haydon, M. Lichinitser, A. Khattak, M.S. Carlino, S. Sandhu, J. Larkin, S. Puig, P.A. Ascierto, P. Rutkowski, D. Schadendorf, R. Koornstra, L. Hernandez-Aya, M. Maio, A.J.v.d. Eertwegh, J.-J. Grob, R. Gutzmer, R. Jamal, P. Lorigan, N. Ibrahim, S. Marreaud, A.C.v. Akkooi, S. Suciu, and C. Robert

N Engl J Med 2018;378:1789-1801

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Participation
Course opens: 
05/09/2018
Course expires: 
05/10/2020

Available Credit

  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Participation

Course closed

This course closed on Sunday, May 10, 2020 - 11:59pm.